European Journal of Nuclear Medicine

, Volume 16, Issue 8–10, pp 755–771 | Cite as

Current role of gallium scanning in the management of lymphoma

  • Andrew F. McLaughlin
  • Michael A. Magee
  • Robert Greenough
  • Kevin C. Allman
  • Andrew E. Southee
  • Steven R. Meikle
  • Brian F. Hutton
  • Douglas E. Joshua
  • George J. Bautovich
  • John G. Morris
Review Article


Gallium 67 scanning in the malignant lympho mas has been done, with variable success, for over 20 years. After initial enthusiasm, the technique fell into disrepute and it was not until the early 1980s that it enjoyed a revival. There have been many major contributions to the literature, both favourable and unfavourable. The reasons for the latter include: poor instrumentation (only single-pulse height analysis), low gallium 67 doses, impatient and careless scanning techniques, timing of the study after treatment (chemotherapy, radiation) and insensitive methods of confirmation of the presence or absence of disease (“truth”). Anatomical diagnostic techniques (computed tomography, plain X-radiography, magnetic resonance imaging and others) are incapable of distinguishing viable tumour in normal size lymph nodes or necrotic/fibrotic residual masses. With improvements in instrumentation (triple-pulse height analysis, gamma camera resolution and tomographic techniques) gallium 67 can detect active tumour in residual masses and in normal-size nodes. This is due to gallium 67's unique ability to localize in viable tumour cells. It has greater than 90% sensitivity, specificity, accuracy and positive predictive value in patients with lymphoma. Its major contributions are in: staging (changing management of mediastinal disease, obviating the need for a laparotomy and clearlyidentifying stage IV disease); detecting relapse or residual, progressive disease (it establishes true complete remission and is often the first and only evidence of relapse before clinical evidence); predicting response to therapy (failure to convert to a negative scan post-treatment signals a poor prognosis and alternative therapy is required); and predicting outcome — prognosis (it is the only diagnostic modality to predict outcome accurately).

Key words

Gallium 67 scanning Lymphoma Hodgkin's disease Non-Hodgkin's Instrumentation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alfrey CP, Lane M, Karjala RJ (1966) Modification of ferrokinetics in man by cancer chemotherapeutic agents. Cancer 19:428–432Google Scholar
  2. Altman KI, Gerber GB, Okada S (1970) In: Radiation biochemistry, vol 2. Academic, New York, p 18Google Scholar
  3. Anderson KC, Leonard RCF, Canellos GP, Skarin AT, Kaplan WD (1983) High dose gallium imaging in lymphoma. Am J Med 75:327–331Google Scholar
  4. Andrews GA, Hubner KF, Greenlaw RH (1978) Gallium-67 citrate imaging in malignant lymphoma: final report of co-operative group. J Nucl Med 19:1013–1019Google Scholar
  5. Anghileri LJ (1973) The mechanism of accumulation of radiogallium and radiolanthanides in tumors. J Nucl Med Biol 17:177–186Google Scholar
  6. Anghileri LJ, Crone-Escanye MC, Thouvenot P, Brunette F, Robert J (1988) Mechanisms of gallium-67 accumulation by tumors: role of cell membrane permeability. J Nucl Med 29:663–668Google Scholar
  7. Aulbert E, Gebhardt A, Schulz E (1976) Isolation of the 67-gallium accumulating fraction in normal rat liver. Nuklearmedizin 15:185–194Google Scholar
  8. Bakshi SP, Parthasarathy KL (1974) Combination of laxatives for cleansing of67Ga-citrate activity in the bowel. J Nucl Med 15:470Google Scholar
  9. Bekerman C, Pavel DG, Bitran J, Yun Ryo U, Pinsky S (1984) The effects of inadvertent administration of antineoplastic agents prior to Ga-67 injection: concise communication. J Nucl Med 25:430–435Google Scholar
  10. Bekerman C, Hoffer PB, Bitran JD (1985) The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 15:72–103Google Scholar
  11. Blackwell EA, Joshua DE, McLaughlin AF, Green D, Kronenberg H, May J (1986) Early supra-diaphragmatic Hodgkin's disease. High dose gallium scanning obviates the need for staging laparotomy. Cancer 58:883–885Google Scholar
  12. Bradley WP, Alderson PO, Eckelman WC, Hamilton RG, Weiss JF (1978) Decreased tumor uptake of gallium-67 in animals after whole-body irradiation. J Nucl Med 19:204–209Google Scholar
  13. Bradley P, Alderson PO, Weiss JF (1979) Effect of iron deficiency on the biodistribution and tumor uptake of Ga-67 citrate in animals: concise communication. J Nucl Med 20:243–247Google Scholar
  14. Brascho DJ, Durant JR, Green LE (1977) The accuracy of retroperitoneal ultrasonography in Hodgkin's disease and non-Hodgkin's lymphoma. Radiology 125:485–487Google Scholar
  15. Brown DH, Swartzendruber DC, Carlton JE (1973) The isolation and characterization of gallium-binding granules from soft tissue tumors. J Nucl Med Biol 17:177–186Google Scholar
  16. Brown DH, Byrd BL, Carlton JE, Swartzendruber DC, Hayes RL (1976) A quantitative study of the subcellular localization of67Ga. Cancer Res 36:956–963Google Scholar
  17. Cabanillas F, Zoroza J, Haynie T, Rodriguez V (1977) Comparison of lymphangiograms and gallium scans in the non-Hodgkin's lymphomas. Cancer 39:85–88Google Scholar
  18. Canellos GP (1988) Residual mass in lymphoma may not be residual disease (editorial). J Clin Oncol 6:931–933Google Scholar
  19. Caride VJ, Gottschalk A (1977) Recent advances in cancer diagnosis in nuclear medicine techniques. Cancer 40:495–499Google Scholar
  20. Clausen J, Edeling CJ, Fogh J (1974) Ga-67 binding to human serum protein and tumor components. Cancer Res 34:1931–1937Google Scholar
  21. DeVito RP, Stoub EW, Siegel ME (1986) Weighted acquisition using finite spatial filters for real-time scatter removal. J Nucl Med 27:960Google Scholar
  22. Dienstvier Z, Bechyne M, Cerna J, Rezny Z (1978) Scintigraphy methods in the diagnosis of M. Hodgkin. Eur J Nucl Med 3:11–14Google Scholar
  23. Donahue DM, Leonard JC, Basmadjian GP, Nitschke RM, Hinkle GH, Loe RD, Wilson DA, Tunell WP (1981) Thymic gallium-67 localization in pediatric patients on chemotherapy: concise communication. J Nucl Med 22:1043–1048Google Scholar
  24. Dudley HC, Imirie GW Jr, Istock JT (1950) Deposition of radiogallium (72Ga) in proliferating tissues. Radiology 55:571–578Google Scholar
  25. Edwards CL, Hayes RL (1969) Tumor scanning with67Ga citrate. J Nucl Med 10:103–105Google Scholar
  26. Edwards CL, Hayes RL (1970) Scanning malignant neoplasms with gallium-67. J Am Med Assoc 212:1182–1190Google Scholar
  27. Fletcher JW, Herbig FK, Donati FM (1975)67Ga citrate distribution following whole-body irradiation or chemotherapy. Radiology 117:709–712Google Scholar
  28. Font D, Israel O (1989) Nuclear medicine in monitoring response to cancer treatment (editorial). J Nucl Med 30:1731–1736Google Scholar
  29. Gomez GA, Reese PA, Nava H, Panahon AM, Barcos M, Stutzman L, Han T, Henderson ES (1984) Staging laparotomy and splenectomy in early Hodgkin's disease, no therapeutic benefit. Am J Med 77:205–210Google Scholar
  30. Greenlaw RH, Weinstein MB, Brill AB, McBain JK, Murphy L, Kniseley RM (1974)67Ga-citrate imaging in untreated malignant lymphoma: preliminary report of cooperative group. J Nucl Med 15:404–407Google Scholar
  31. Gunasekera S, King LT, Lavender PJ (1972) The behaviour of trace gallium-67 towards serum proteins. Clinica Chim Acta 39:401–406Google Scholar
  32. Hammersley PAG (1984) Relative tumour enhancement of67Ga uptake by desferrioxamine. Eur J Nucl Med 9:467–471Google Scholar
  33. Hammersley PAG, Zivanovic MA (1976) Gallium-67 uptake in the regenerating rat liver. J Nucl Med 17:226Google Scholar
  34. Harris AW, Sephton RG (1977) Transferrin promotion of67Ga and59Fe uptake by cultured mouse myeloma cells. Cancer Res 37:3634–3638Google Scholar
  35. Harris WR, Pecoraro VL (1983) Thermodynamic binding constants for gallium transferrin. Biochemistry 22:292–299Google Scholar
  36. Hartman RE, Hayes RE (1969) The binding of gallium by blood serum. J Pharmacol Exp Ther 168:193–198Google Scholar
  37. Hayes RE (1976) Factors affecting uptake of radioactive agents by tumour and other tissues. In: Tumour localization with radioactive agents. Vienna, IAEA, pp 29–40Google Scholar
  38. Hayes RL, Carlton JE (1973) A study of macro molecular binding of67Ga in normal and malignant animal tissue. Cancer Res 33:3265–3272Google Scholar
  39. Hayes RL, Edwards CL (1973) The effect of stable scandium on red blood cells and on the retention and excretion of 67-Ga in humans. South Med J 66:1339–1340Google Scholar
  40. Hayes RL, Carlton JE, Byrd BL (1965) Bone scanning with gallium-68: a carrier effect. J Nucl Med 6:605–610Google Scholar
  41. Hayes RL, Carlton JE, Byrd BL (1969) Factors affecting localization of 67-gallium in animal tumors. J Nucl Med 10:406Google Scholar
  42. Hayes RL, Byrd BL, Rafter JJ, Carlton JE (1980) The effect of scandium on the tissue distribution of Ga-67 in normal and tumor-bearing rodents. J Nucl Med 21:361–365Google Scholar
  43. Hayes RL, Rafter JJ, Byrd BL, Carlton JE (1981) Studies of the in vivo entry of Ga-67 into normal and malignant tissue. J Nucl Med 22:325–332Google Scholar
  44. Henkin RE, Polcyn RE, Quinn JL III (1974) Scanning treated Hodgkin's disease with 67 Ga citrate. Radiology 110:151–154Google Scholar
  45. Herman T, Jones S (1976) Systematic restaging in patients with Hodgkin's disease: a southwest oncology group study. Cancer 42:1976–1982Google Scholar
  46. Hoffer PB (1978a) Mechanisms of localization. In: Hoffer PB, Bekerman C, Henkin RE (eds) Gallium-67 imaging. John Wiley, New York, pp 4–8Google Scholar
  47. Hoffer PB (1978b) The utility of gallium-67 in tumour imaging: a comment on the final reports of the co-operative study group. J Nucl Med 19:1082–1083Google Scholar
  48. Hoffer PB, Huberty J, Khayam-Bashi H (1977a) The association of Ga-67 and lactoferrin. J Nucl Med 18:713–717Google Scholar
  49. Hoffer PB, Schor R, Ashby D, Metz C, Hattner R, Handmaker H, Price DC, Shames DM, Lilien D, Lim CE (1977b) Comparison with Ga-67 citrate images obtained with rectilinear scanner and large-field Anger camera. J Nucl Med 18:538–541Google Scholar
  50. Hoffer PB, Samuel A, Bushberg T, Thakur M (1979) Effect of desferrioxamine on tissue and tumor retention of gallium-67: concise communication. J Nucl Med 20:248–251Google Scholar
  51. Horn NL, Ray GR, Kriss JP (1976) Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer 37:250–257Google Scholar
  52. Hurst R, Sabio H, Teates CD (1988) Gallium-67 uptake in thymic rebound. South Med J 81:1167–1169Google Scholar
  53. Hutton BF, Smart R, Fulton RR (1983) Contrast quantitation as a screening test of gamma camera performance. Aust NZ J Med 13:656Google Scholar
  54. Hays J, Schelstraete K, Simons M (1982) Gallium-67 imaging in Hodgkin's disease. Clin Nucl Med 7:174–179Google Scholar
  55. Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y (1985) Uptake of gallium-67 citrate and 2-H-3 deoxyglucose in the tumour model, following chemotherapy and radiotherapy. J Nucl Med 26:278–282Google Scholar
  56. Israel O, Front D, Menachem L, Ben-Haim S, Kleinhaus U, Ben-Shachar M, Robinson E, Kolodny GM (1978) Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer 61:2439–2443Google Scholar
  57. Ito Y, Okuyama S, Sato K, Takahashi K, Sato T, Kanno I (1971) 67-Ga tumor scanning and its mechanism studied in rabbits. Radiology 100:357–362Google Scholar
  58. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G (1985) The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 3:637–640Google Scholar
  59. Jochelson MS, Herman TS, Stomper PC, Mauch PM, Kaplan WD (1988) Planning mantle radiation therapy in patients with Hodgkin's disease: role of gallium-67 scintigraphy. Am J Roentgenol 151:1229–1231Google Scholar
  60. Johnston GS, Benua RS, Teates CD, Edwards CL, Kniseley RM (1974)67Ga-citrate imaging in untreated Hodgkin's disease: preliminary report of cooperative group. J Nucl Med 15:399–407Google Scholar
  61. Johnston GS, Mae FG, Benua RS, Larson SM, Andrews GA, Hubner KF (1977) Gallium-67 citrate imaging in Hodgkin's disease: final report of cooperative group. J Nucl Med 18:692–698Google Scholar
  62. Joshua DE, Dalgleish A, Kroneberg H (1984) Is staging laparotomy necessary in patients with supra-diaphragmatic Stage I and Ila Hodgkin's disease? Lancet 1:847–848Google Scholar
  63. Joshua DE, McLaughlin AF, Kronenberg H, Bautovich GJ, Morris JG, Wylie BR, Southee AE, Gibson J (1989) Residual mass and gallium scanning (letter to editor). J Clin Oncol 7:144–145Google Scholar
  64. Kaplan WD, Anderson KC, Leonard RCF (1983) High dose gallium imaging in the evaluation of lymphoma. J Nucl Med 24:50Google Scholar
  65. Kaplan WD, Jochelson M, Herman T, Stomper P (1988) Use of gallium-67 citrate (Ga-67) to predict response to therapy of diffuse, large cell lymphoma (DLCL). J Nucl Med 29:799Google Scholar
  66. Kay DN, McReady VR (1972) Clinical isotope scanning using67Ga citrate in the management of Hodgkin's disease. Br J Radiol 45:437–443Google Scholar
  67. King DJ, Dowson AA, McDonald AF (1980) Gallium scanning in lymphoma. Clin Radiol 31:729–732Google Scholar
  68. Kohno H, Lizuka Y, Suzuki T, Ohkubo Y, Kubodera A (1985) Developmental changes in tissue distributions of gallium-67 citrate. J Nucl Med 26:761–764Google Scholar
  69. Larson SM, Carrasquillo JA (1988) Nuclear oncology: current perspectives. In: Freeman, Weissmann (eds) Nuclear medicine annual. Raven, New York, pp 167–198Google Scholar
  70. Larson SM, Hoffer PB (1978) Normal patterns of localization. In: Hoffer PB, Bekerman C, Henkin RE (eds) Gallium-67 imaging. John Wiley, New York, pp 23–28Google Scholar
  71. Larson SM, Allen DR, Rasey JS, Grunbaum Z (1978) Kinetics of binding of carrier-free Ga-67 to human transferrin. J Nucl Med 19:1245–1249Google Scholar
  72. Larson SM, Rasey JS, Allen DR, Nelson NJ (1979a) A transferrin mediated uptake of gallium-67 by EMT-6 sarcoma. I Studies in tissue culture. J Nucl Med 20:837–842Google Scholar
  73. Larson SM, Rasey JS, Allen DR, Grunbaum Z (1979b) A transferrin mediated uptake of gallium-67 by EMT-6 sarcomas. II Studies in vivo (BALB/C mice). J Nucl Med 20:843–846Google Scholar
  74. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, Williams DL (1980) Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 64:41–53Google Scholar
  75. Lavender JP, Lowe J, Barker JR, Burn JI, Chaudhri MA (1971) Gallium-67 scanning in neoplastic and inflammatory lesions. Br J Radiol 44:361–366Google Scholar
  76. Lentle BC, Castor WR, Khalig A, Dierich H (1975) The effect of contrast lymphangiography on localization of67Ga-citrate. J Nucl Med 16:374–376Google Scholar
  77. Levi JA, O'Connell MJ, Murphy WL, Sutherland JC, Wiernik PH (1975) Role of 67 gallium citrate scanning in the management of non-Hodgkin's lymphoma. Cancer 36:1690–1701Google Scholar
  78. Lister TA, Crowther T, Sutcliffe SB, Canellos GP, Young RC, Resenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630–1636Google Scholar
  79. Loisillier F, Got R, Burtin P, Grabar P (1966) Recherches sur la localisation tissulaire et l'autoantigenicité de la lactotransferrine. Protides Biol Fluids 14:133–142Google Scholar
  80. Longo DL, Schilsky RL, Blei L, Cano R, Johnston GS, Young RC (1980) Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. Am J Med 68:695–700Google Scholar
  81. Martin JJ, Sephton RG (1978) Gallium-67 scanning in the malignant lymphomas. Aust Radiol 22:340–346Google Scholar
  82. McCaffrey JA, Rudders RA, Kahn PC, Harvey HA, De Lellis RA (1976) Clinical usefulness of67gallium scanning in the malignant lymphomas. Am J Med 60:523–530Google Scholar
  83. McCready VR, Dance DR, Hammersley P, Nash A, Peckham MJ (1973) Clinical and experimental observations on gallium-67 citrate uptake in Hodgkin's and other diseases. IAEA, Vienna, pp 565–581Google Scholar
  84. McLaughlin AF, Chu J, Howman-Giles R (1981) Whole body gallium scanning in malignant lymphoma — its role in 1980. Aust NZ J Med 11:436Google Scholar
  85. Murray KJ, Elliott AT, Wadsworth J (1979) A new phantom for the assessment of nuclear medicine imaging equipment. Phys Med Biol 24:188–192Google Scholar
  86. Nelson B, Hayes RL, Edwards CL, Kniseley RM, Andrews GA (1972) Distribution of gallium in human tissues after intravenous administration. J Nucl Med 13:92–100Google Scholar
  87. Neumann RD, Hoffer PB (1988) Gallium for detection of malignant disease. In: Gottschalk A, Hoffer PB, Potchen E (eds) Diagnostic nuclear medicine, vol 2. Williams and Wilkins, Baltimore, pp 1078–1081Google Scholar
  88. Noujaim AA, Turner CJ, Van Niewwenhuyze BM, Turner U, Lentle BC (1981) An investigation of the mechanism ofcis-diamine dichloroplatinum (cis-pt) interference with radiogallium uptake in tumors. Aust NZ J Med 11:437Google Scholar
  89. O'Donnell JK, Cordasco EM, Go RT (1985) Improved evaluation of pulmonary sarcoidosis with Ga-67 transaxial emission tomography. Radiology 157:155Google Scholar
  90. Orii H (1972) Tumor scanning with gallium (67Ga) and its mechanism studied in rats. Strahlentherapie 144:192–200Google Scholar
  91. Paterson AHG, McCready VR (1975a) Review article: tumour imaging radiopharmaceuticals. Br J Radiol 48:520–531Google Scholar
  92. Paterson AHG, McCready VR (1975b) The current status of gallium 67 scanning. Br J Radiol 48:944Google Scholar
  93. Pinsky SM, Henkin RE (1976) Gallium-67 tumour scanning. Semin Nucl Med 4:397–409Google Scholar
  94. Potchen EJ, Elliott AJ, Siegel BA, Struder R, Evens RG (1971) Pathophysiological basis of soft tissue tumor scanning. J Surg Oncol 3:593–602Google Scholar
  95. Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, Eddleston B (1988) The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 6:940–946Google Scholar
  96. Rudders R, McCaffrey JA, Kahn P (1977) The relative roles of gallium-67 citrate scanning and lymphangiography in the current management of malignant lymphoma. Cancer 40:1439–1443Google Scholar
  97. Scheffel U, Tsan ME (1980) Effect of serum unbound iron-binding capacity on the tissue distribution of67Ga in abscess bearing rabbits. Nuklearmedizin 19:274Google Scholar
  98. Sephton RG, Harris AW (1975) Gallium-67 citrate uptake by cultured tumor cells, stimulated by serum transferrin. J Natl Cancer Inst 54:1263–1266Google Scholar
  99. Sethi VS, Shihabi Z, Spurr CI (1984) Increase of serum iron concentrations in rhesus monkeys and humans on administration of vincristine, vinblastine or vindesine. Cancer Treat Rep 68:933–936Google Scholar
  100. Siegel ME, Lee KH, DeVito RP, Chen O, Chen DCP (1986) Weighted acquisition: a method for improving bone and gallium images. J Nucl Med 27:988Google Scholar
  101. Silberstein EB (1976) Cancer diagnosis, the role of tumor-imaging radiopharmaceuticals. Am J Med 60:226–236Google Scholar
  102. Smith FW, Dendy PP (1981) Modification of gallium-67 citrate distributions in man following the administration of iron. Br J Radiol 54:398–402Google Scholar
  103. Southee AE, Wylie BR, McLaughlin AF, Joshua DE, Kronenberg H, Morris JG (1988) Gallium scintigraphy in the management of mediastinal Hodgkin's disease. Aust NZ J Med 18:508Google Scholar
  104. Southee AE, McLaughlin AF, Joshua DE, Bautovich GJ, Hutton BF, Wylie BR, Kronenberg H, Morris JG (1989) Gallium scanning as a predictor of outcome in mediastinal Hodgkin's disease. Eur J Nucl Med 15:547Google Scholar
  105. Swartzendruber DC, Nelson B, Hayes RL (1971) Gallium-67 1oca1isation in lysosomal-like granules of leukemic and nonleukemic murine tissues. J Natl Cancer Inst. 46:941–952Google Scholar
  106. Swartzendruber DC, Hubern KF (1973) Effect of external whole body X-irradiation on gallium-67 retention in mouse tissues. Radiat Res 55:457–468Google Scholar
  107. Takeda S, Uchida T, Matsuzawa T (1977) A comparative study on lysosomal accumulation of gallium-67 and indium-111 in Morris hepatoma 731GA. J Nucl Med 18:835–839Google Scholar
  108. Thomas F, Cosset JM, Cherel P, Renaudy N, Carde P, Piekarski JD (1988) Thoracic CT-scanning follow-up of residual masses after treatment of Hodgkin's disease. Radiother Oncol 11:119–122Google Scholar
  109. Tsan MF, Schefel U, Tsen KY, Camago EE (1980) Factors affecting the binding of gallium-67 in serum. Int J Nuc Med Biol 7:270–273Google Scholar
  110. Tsan MF, Scheffel U (1986) Mechanism of gallium-67 accumulation in tumors. J Nucl Med 27:1215–1219Google Scholar
  111. Tsan MF, Scheffel U (1988) Mechanism of gallium-67 accumulation in tumors. J Nucl Med 29:2019–2020Google Scholar
  112. Tumeh SS, Rosenthal DS, Kaplan WD, English RJ, Holman BL (1987) Lymphoma: evaluation with Ga-67 SPECT. Radiology 164:111–114Google Scholar
  113. Turner DA, Pinsky SM, Gottschalk A, Hoffer PB, Ultmann JE, Harper PB (1972) The use of 67-Ga scanning in the staging of Hodgkin's disease. Radiology 103:97–101Google Scholar
  114. Turner DA, Gottschalk A, Hoffer PB, Harper PV, Morgan E, Ultmann JE (1973) Gallium-67 scanning in the staging of Hodgkin's disease. IAEA, Vienna, pp 615–629Google Scholar
  115. Turner DA, Fordham EW, Slayton RE (1978a) Malignant lymphoma. In: Hoffer PB, Bekerman C, Henkin RE (eds) Gallium-67 imaging. John Wylie, New York, pp 95–112Google Scholar
  116. Turner DA, Fordham EW, Ali A, Slayton RE (1978b) Gallium-67 imaging in the management of Hodgkin's disease and other malignant lymphomas. Semin Nucl Med 8:205–218Google Scholar
  117. Ultman JE, Jacobs RH (1985) The non-Hodgkin's lymphomas. CA 35:66–87Google Scholar
  118. Vallabhajosula SR, Harwig JF, Siemsen JK, Wolf W (1980) Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med 21:650–656Google Scholar
  119. Vallabhajosula SR, Harwig JF, Wolf W (1982) Effect of pH on tumour cell uptake of radiogallium in vitro and in vivo. Eur J Nucl Med 7:462–468Google Scholar
  120. Vallabhajosula S, Goldsmith SJ, Lipszyc H, Chahinian AP, Ohnuma T (1983)67Ga-transferrin and67Ga-lactoferrin binding to tumor cells: specific versus nonspecific glycoprotein-cell interaction. Eur J Nucl Med 8:354–357Google Scholar
  121. White L, Miller J, Reid B (1984) Preoperative ultrasound and gallium-67 evaluation of abdominal non-Hodgkin's lymphoma. Am J Dis Child 138:740–745Google Scholar
  122. Winchell HS (1976) Mechanisms for localization of radiopharmaceuticals in neoplasms. Semin Nucl Med 6:371–378Google Scholar
  123. Wylie BR, Southee AE, Joshua DE, McLaughlin AF, Gibson J, Hutton BF, Morris JG, Kronenberg H (1989) Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 42:344–347Google Scholar
  124. Yang SL, Alderson PO, Kaizer HA, Wagner HN Jr (1979) Serial Ga-67 citrate imaging in children with neoplastic disease: concise communication. J Nucl Med 20:210–214Google Scholar
  125. Zeman RK, Ryerson TW (1977) The value of bowel preparations in Ga-67 citrate scanning: concise communication. J Nucl Med 18:886–889Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Andrew F. McLaughlin
    • 1
  • Michael A. Magee
    • 1
  • Robert Greenough
    • 1
  • Kevin C. Allman
    • 1
  • Andrew E. Southee
    • 1
  • Steven R. Meikle
    • 1
  • Brian F. Hutton
    • 1
  • Douglas E. Joshua
    • 2
  • George J. Bautovich
    • 1
  • John G. Morris
    • 1
  1. 1.Department of Nuclear MedicineRoyal Prince Alfred HospitalCamperdownAustralia
  2. 2.Department of HaematologyRoyal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations